The capacity to regulate the biodistribution of therapeutics is a highly desired feature that can limit the side effects of many drugs. In a new study in Scientific Reports, Noah Joseph, and a team of biotechnology and nanoscience scientists in Israel, describe a nanoscale agent developed from a coupled polymer-DNA origami hybrid capable of exhibiting stability in serum and slow diffusion through tissues.
By coupling to fragments of polyethylene glycol through polyamine electrostatic interactions, the team noted marked stability of the agents in vivo, where more than 90% of the constituents maintained structural integrity for five days after subcutaneous injection.
The findings highlight the polymer-DNA hybrid nanostructures as viable pharmacological agents that can enter mainstream technologies, including their use as monoclonal antibodies for drug activity.
Leave a reply